Journal of Clinical Oncology
Articles in this Issue
Neoadjuvant and adjuvant iruplinalkib in resectable <i>ALK</i> or <i>ROS1</i> fusion-positive, non-small cell lung cancer (NSCLC): The preliminary results of the single-arm, exploratory Neo-INFINITY study.
e20044 Background: The ALNEO, NAUTIKA1, and SAKULA studies found perioperative alectinib and ceritinib were effective for resectable ALK...
Addressing lung cancer screening gaps in refugee populations: Insights from a retrospective cohort in upstate New York.
e22532 Background: Lung cancer screening (LCS) prevalence is low (16.4% in 2022) in eligible patients nationally and may be lower in high-risk groups. Ref...
A multi-epitope mRNA vaccine for effective immunotherapy in esophageal squamous cell carcinoma.
e16007 Background: Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with limited treatment options, particularly in patients wh...
Memantine in radiation-induced cognitive dysfunction in brain metastases: A double-blinded, randomized, placebo-controlled trial (CTRI/2022/01/039599).
2036 Background: Prospective double-blinded, placebo-controlled randomized study to evaluate the role of memantine in brain metastasis (BM) in preserving...
OP-35: Does a tool designed to measure potentially preventable chemotherapy toxicities do so effectively?
1538 Background: OP-35 is a measure developed by the National Quality Foundation that the Center for Medicare and Medicaid Services (CMS) uses to evaluate...
Transarterial chemoembolization plus donafenib and immune checkpoint inhibitors for intermediate hepatocellular carcinoma (CHANCE2410): A propensity score matching analysis.
4126 Background: Hepatocellular carcinoma (HCC) has high incidence and mortality, with over 80% of patients diagnosed at intermediate or advanced stages,...
Machine learning–based identification of a metabolic gene prognostic signature (MALMPS) model to investigate the clinical and molecular heterogeneity of stage II/III colorectal cancer.
e15548 Background: Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes, and stage II/III CRC accounts for nearly 70%. Metab...
Effect of 18F-DOPA-PET and advanced MRI on treatment response assessment in IDH1/2-mutant gliomas treated with IDH inhibitors.
2050 Background: Small-molecule inhibitors targeting IDH1/2-mutant proteins (IDHi) have shown promise as treatments for IDH1/2 -mu...
FOLFIRINOX: The best adjuvant treatment for ampullary adenocarcinoma?
e16261 Background: Ampullary adenocarcinoma is a rare cancer for which there are no standard adjuvant treatment recommendations due to the lack of randomi...
Five-year cardiomyopathy risk prediction in survivors of childhood cancer using electrocardiogram.
10022 Background: Childhood cancer survivors (CCS) face an increased risk of developing cardiomyopathy during adult life due to late onset of treatment (e...
Protocol quality for patient-reported outcomes in multiple myeloma randomized controlled trials according to the SPIRIT-PRO guidelines: A systematic review.
e23189 Background: Patient-reported outcomes (PROs) are increasingly incorporated into multiple myeloma (MM) randomized controlled trials (RCTs) to help i...
The prognostic value of acneiform rash grade in metastatic colorectal cancer patients treated with EGFR inhibitors.
e15599 Background: Epidermal growth factor receptor inhibitors (EGFRis), such as cetuximab and panitumumab, are widely used in the treatment of metastatic...
Ethnic and racial disparities in sebaceous gland carcinoma of the eyelid: A SEER database analysis.
e18055 Background: Meibomian gland tumors are rare neoplasms originating from the sebaceous glands of the eyelids. Recognizing the racial disparities in t...
Multicenter real-world study of trastuzumab combined with pirotinib or pertuzumab as a neoadjuvant therapy for stage II-III HER-2 positive breast cancer.
e12609 Background: Neoadjuvant therapy is an important treatment strategy for HER-2 positive early breast cancer and Trastuzumab combined with Pertuzumab...
A phase II study of anlotinib plus penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Results from ALTER-GO-020 trial.
5527 Background: In patients with recurrent, or metastatic cervical cancer, atezolizumab combined with bevacizumab and chemotherapy has significantly enha...
Longitudinal risk of physical functional impairment and health care utilization in cancer survivors within 3 years of diagnosis.
11081 Background: Despite known physical functional (PF) impairment in cancer survivors, patterns of its development and relationships to healthcare utili...
Oncoshare-Lung: Novel three-way linkage of neighboring academic and community medical centers to state cancer registry for lung cancer.
e23292 Background: Clinical research conducted at academic medical centers is often limited by fragmented patient history, which can be enhanced by integr...
Implementation of tarlatamab treatment for small cell lung cancer using an outpatient care program.
8106 Background: Tarlatamab, a bispecific T-cell engager targeting DLL3, was FDA approved for relapsed small cell lung cancer (SCLC) in May 2024. It requi...
Phase II trial of neoadjuvant nivolumab and SOX in resectable gastric/gastroesophageal junction cancer: Therapeutic response and biomarker correlations.
2622 Background: Neoadjuvant immunotherapy produces a major pathologic response (MPR) in 40% of patients with locally advanced gastric cancer (LAGC). Here...
Safety and tolerability of dostarlimab in combination antiretroviral therapy–refractory HIV-associated Kaposi sarcoma: Preliminary results from the StarKap phase Ib trial.
e14588 Background: HIV-associated Kaposi’s Sarcoma (KS) is a rare malignancy associated with Human Herpesvirus-8 (HHV-8) in people living with HIV. Progra...
Distinct effect of neoadjuvant PD1 alone, PD1+IPI, and PD1+lenvatinib in the peripheral immune profile of melanoma patients (pts) and correlation with pathological (path) response.
9568 Background: Neoadjuvant immunotherapy (NeoIT) has significantly improved clinical outcomes for pts with macroscopic stage III resectable melanoma and...
An open-label, phase Ib trial of the SIRPα inhibitor BI 765063 in combination with the PD-1 inhibitor ezabenlimab and cetuximab in patients (pts) with head and neck squamous cell carcinoma.
6019 Background: BI 765063 is a first-in-class, humanized IgG4 monoclonal antibody that binds the V1 allele of signal regulatory protein α (SIRPα) and blo...
Procedure for pooling clinical outcome data from DRUP-like clinical trials using the OMOP model.
e23165 Background: PRIME-ROSE is a European Cancer Mission project focused on advancing precision cancer medicine (PCM) trials and innovative processes fo...
Significance of changes in serum LDH and HBDH in predicting the efficacy of first-line chemoimmunotherapy in small cell lung cancer.
e20107 Background: The aim of this retrospective cohort study was to investigate small-cell lung cancer (SCLC) patients' clinical correlates of lactate de...
Assessment of the impact of delays to radiotherapy on prostate cancer mortality in localized prostate cancer.
5100 Background: Resource constraints and patient preferences may lead to delays in the treatment of localized prostate cancer, but the implications of su...